WELDING PHARMA API is proud to announce an exclusive partnership with CHEMISCHE FABRIK BERG for the development, manufacture and commercialization of Lisdexamfetamine dimesilate. Building on more than two decades of trusted collaboration in pharmaceutical APIs, this strategic partnership marks a significant new milestone in the relationship between the two companies. It is founded on mutual […]
Read More
WELDING FEED, part of the WELDING Group, is deepening its collaboration with WELDING FOOD and its partner Eurogum – Bang & Bonsomer. By combining feed and food expertise, the partners support pet food manufacturers in developing reliable, high-quality products. Following their joint presence at Interzoo in Nuremberg earlier this year, WELDING FEED recently welcomed a […]
Read More
Quinine 200 mg Film-Coated Tablets (DCP Start) The company has started the Decentralized Procedure (DCP) for Quinine 200 mg Film-Coated Tablets, marking a new step in the expansion of its European generic portfolio. Building on decades of experience in bringing high-quality, value-oriented pharmaceutical solutions to market, WELDING is pursuing this application in line with […]
Read More
WELDING GmbH & Co. KG announces an important regulatory milestone in Europe. Following the successful closure of the Decentralized Procedure (DCP) earlier this year, WELDING GmbH & Co. KG in collaboration with its partner Zenara Pharma Pvt Ltd has received its first marketing authorizations in Europe for Tafamidis 61 mg soft capsules. WELDING is among the […]
Read More
WELDING GmbH & Co. KG announces the establishment of its Mexican subsidiary, WELDING Ingredientes SA de CV. With this step, our family-owned company is expanding its international presence and strengthening its position in the Latin American market. Our goal is to combine our long-standing European distribution expertise and global sourcing network with local market knowledge […]
Read MoreRevio Therapeutics ("Revio") and Welding Group ("Welding") today announced the signing of a co-development and licensing agreement for Revio’s proprietary specialty oncology product. The 505(b)(2) product, designed based on an innovative dosage form with significant patient compliance and ease-of-use advantages, will be developed by Revio and commercialized by Welding through the partnership across the United States, Europe, and […]
Read More